TFRC and central nervous system cancer: Mice bearing TfR+ gliomas and that had received i.v. PAMAM-PEG-TfR/TMZ, also showed an MST of 66.4 ± 11.9 days (95% CI, 57.9 – 74.9 days), which was significantly longer as compared to that of TfR-cell implanted mice and PAMAM/TMZ administration (P < 0.01).